Abstract
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11–55 years.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Sáez-Llorens, X. & McCracken, G. H. Jr. Bacterial meningitis in children. Lancet 361, 2139–2148 (2003).
Harrison, L. H. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev. 19, 142–164 (2006).
Bröker, M. et al. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 27, 5574–5580 (2009).
US Food and Drug Administration. FDA labelling information — Menveo. FDA website [online], (2010).
Arguedas, A. et al. Safety and immunogenicity of one dose of MenACWY–CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 28, 3171–3179 (2010).
Harrison, L. H. Trotter, C. L. & Ramsay M. E. Global epidemiology of meningococcal disease. Vaccine 27 (Suppl. 2), B51–B63 (2009).
Centers for Disease Control and Prevention. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 59, 273 (2010).
Snape, M. D. et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299, 173–184 (2008).
Nolan, T. et al. A novel combined Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y–tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine 25, 8487–8499 (2007).
Lee, C. H. et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 27, 726–732 (2009).
Giuliani, M. M. et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103, 10834–10839 (2006).
Fletcher, L. D. et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72, 2088–2100 (2004).
Cohn, A. C. et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50, 184–191 (2010).
Sanofi–Aventis. Annual report 2009 (Sanofi–Aventis, France, 2009).
Baum, A. Morgan Stanley analyst report. (Jan 2009).
Lanone, P. Natixis Securities analyst report. (May 2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Lee H. Harrison has received a career development award from the National Institute of Allergy and Infectious Diseases (K24 AI52788), and receives research funding from Sanofi Pasteur. He has received consulting fees and speaking honoraria from Sanofi Pasteur, Novartis, Merck, Wyeth and GlaxoSmithKline.
Rights and permissions
About this article
Cite this article
Harrison, L., Mohan, N. & Kirkpatrick, P. Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov 9, 429–430 (2010). https://doi.org/10.1038/nrd3194
Issue date:
DOI: https://doi.org/10.1038/nrd3194
This article is cited by
-
Development and Immunogenicity of a Brazilian Glycoconjugate vaccine against Meningococcal W in a Pilot Scale
Glycoconjugate Journal (2021)
-
Pediatric meningococcocal meningitis in the acute phase: how much does it cost?
Italian Journal of Pediatrics (2019)
-
Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies
Nature Communications (2019)
-
Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection
Scientific Reports (2018)
